TO STUDY CLINICAL PROFILE OF ANEMIAAND EFFECT OF ERYTHROPOIETIN IN CHRONIC KIDNEY DISEASES PATIENT

Dr. Khushbu Rajesh Patel, Dr. Krishna K. Lakhani

Abstract


• Chronic Kidney Disease (CKD) is a major health care problem worldwide, with a global prevalence of 8-16%.1 With the increase in the life expectancy and increase in the prevalence of lifestyle disease there is increase in prevalence of CKD.

• The kidney disease outcome quality initiative (KDOQI) of

National Kidney Foundation’s guideline defines CKD “as kidney damage or estimated GFR (GFR<60 ml/min/1.73m2) for more than equal to 3 months”2.

• Chronic Kidney Disease leads to a wide range of systemic derangements. Anemia is a very common manifestation among patients of CKD.3,4As the renal dysfunction increases in severity, there is proportional increase in prevalence and severity of hematological impairment. .


Keywords


Chronic Kidney Disease (CKD), kidney disease outcome quality initiative (KDOQI), National Kidney Foundation, Pathophysiologically

Full Text:

PDF

Refbacks

  • There are currently no refbacks.